hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-03. Numbers and descriptions here follow the published literature rather than marketing material.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
In Indonesia, the hardline anti-communist General Suharto wrested control from predecessor Sukarno in an attempt to establish a "New Order". From 1965 to 1966, with the aid of the US and other Western governments, the military led the mass killing of more than 500,000 members and sympathizers of the Indonesian Communist Party and other leftist organizations, and detained hundreds of thousands in prison camps under inhumane conditions. A top-secret CIA report stated that the massacres "rank as one of the worst mass murders of the 20th century, along with the Soviet purges of the 1930s, the Nazi mass murders during the Second World War, and the Maoist bloodbath of the early 1950s." These killings served US interests and constitute a major turning point in the Cold War as the balance of power shifted in Southeast Asia.
Have a diagnosable opioid use disorder, according to the DSM-5, Be actively addicted to opioids at the time of intake, and Have been addicted to opioids for at least one year before beginning treatment. In addition to these federal criteria, each state may have its own criteria individuals must meet. The US GAO also cited the cost of treatment and lack of health insurance coverage for MAT as barriers for many addicted to opioids. While methadone treatments are covered by Medicaid for low-income individuals, the extent of coverage depends on which state they are in and if the state has opted into Medicaid expansion under the Affordable Care Act. Buprenorphine, on the other hand, is not covered by Medicaid or, often, even by private health insurers. Because buprenorphine must typically be paid for out-of-pocket, lower-income individuals are often priced out of the lower-risk MAT. In some areas this creates major disparities along racial lines with the higher-risk treatment utilized by lower-income individuals - disproportionately represented by people of color - and the lower-risk treatment only accessible to higher-income individuals - disproportionately represented by whites. Other individual-level barriers may include transportation, especially for those who live in rural areas. The nearest Opioid Treatment Program (OTP) could be up to an hour away, and when daily methadone doses are required for treatment, this may interfere with the success of the MAT or the client's compliance in the program.
=== Synthetic hydrogel dressings === Synthetic hydrogel dressings may be derived from synthetic polymers such as polyvinyl alcohol (PVA), poly(ethylene glycol) (PEG), polyurethane (PU), and poly(lactide-co-glycolide) (PLGA). Synthetic hydrogel dressings may also be formed from designer peptides. Researchers are applying 3D printing to the synthesis of hydrogel dressings.
Freight containers are a reusable transport and storage unit for moving products and raw materials between locations or countries. There are about seventeen million intermodal containers in the world, and a large proportion of the world's long-distance freight generated by international trade is transported in shipping containers. In addition, it is estimated that several million of these containers have now been discarded due to the shipping cost of sending them back to their port of origin. Their invention made a major contribution to the globalization of commerce in the second half of the 20th century, dramatically reducing the cost of transporting goods and hence of long-distance trade. Specialized shipping containers include: high cube containers (providing an extra 1 ft (305 mm) in height to standard shipping containers), pallet wides, open tops, side loaders, double door or tunnel-tainers, and temperature controlled containers. Another specialized container, known as Transtainer, is a portable fuel and oil freight container. The hybrid bulk fuel tank is originally intended for the construction, mining, logging and farming sectors. The tank can be used to transport and store bulk fuels as well as dangerous liquids, by road, rail and sea. Sea containers are crucial for modern logistics, offering a cost-effective storage and shipping solution. These durable containers, designed for international transportation, provide secure storage for goods with robust steel construction. Beyond shipping, they find applications in on-site storage and modular living or workspaces.
Sources: en.wikipedia.org
The National Institutes of Health Clinical Center, the world's largest clinical research hospital, is designed to foster smooth transitions between laboratory work, patient studies, and bedside cures, facilitating the translation of laboratory findings to new approaches for the prevention and cure of human diseases.
==== Mass spectrometry–based methods ==== In mass spectroscopy-based proteomics there are three major steps needed for peptide identification: sample preparation, separation of peptides, and identification of peptides. Several groups have focused on oocytes or very early cleavage-stage cells since these cells are unusually large and provide enough material for analysis. Another approach, single cell proteomics by mass spectrometry (SCoPE-MS) has quantified thousands of proteins in mammalian cells with typical cell sizes (diameter of 10-15 μm) by combining carrier-cells and single-cell barcoding. The second generation, SCoPE2, increased the throughput by automated and miniaturized sample preparation; It also improved quantitative reliability and proteome coverage by data-driven optimization of LC-MS/MS and peptide identification. The sensitivity and consistency of these methods have been further improved by prioritization, and massively parallel sample preparation in nanoliter size droplets. Another direction for single-cell protein analysis is based on a scalable framework of multiplexed data-independent acquisition (plexDIA) enables time saving by parallel analysis of both peptide ions and protein samples, thereby realizing multiplicative gains in throughput. The separation of differently sized proteins can be accomplished by using capillary electrophoresis (CE) or liquid chromatography (LC) (using liquid chromatography with mass spectroscopy is also known as LC-MS). This step gives order to the peptides before quantification using tandem mass-spectroscopy (MS/MS).
For US refrigerators, the Consortium on Energy Efficiency (CEE) further differentiates between Energy Star qualified refrigerators. Tier 1 refrigerators are those that are 20% to 24.9% more efficient than the Federal minimum standards set by the National Appliance Energy Conservation Act (NAECA). Tier 2 are those that are 25% to 29.9% more efficient. Tier 3 is the highest qualification, for those refrigerators that are at least 30% more efficient than Federal standards. About 82% of the Energy Star qualified refrigerators are Tier 1, with 13% qualifying as Tier 2, and just 5% at Tier 3. Besides the standard style of compressor refrigeration used in ordinary household refrigerators and freezers, there are technologies such as absorption and magnetic refrigeration. Although these designs generally use a much more energy than compressor refrigeration, other qualities such as silent operation or the ability to use gas can favor their use in small enclosures, a mobile environment or in environments where failure of refrigeration must not be possible. Many refrigerators made in the 1930s and 1940s were far more efficient than most that were made later. This is partly due to features added later, such as auto-defrost, that reduced efficiency. Additionally, after World War 2, refrigerator style became more important than efficiency. This was especially true in the US in the 1970s, when side-by-side models (known as American fridge-freezers outside of the US) with ice dispensers and water chillers became popular.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.